Am­gen pulls ahead in sprint to­wards CGRP ap­proval with promis­ing PhI­II mi­graine da­ta

The fron­trun­ner in the race to com­mer­cial­ize CGRP mi­graine med­ica­tions just picked up some added mo­men­tum. Am­gen $AMGN has pub­lished promis­ing Phase III da­ta that might lend to its ap­proval, keep­ing the com­pa­ny — and its part­ner No­var­tis — ahead of its many com­peti­tors in the crowd­ed space.

The drug, re­cent­ly coined Aimovig (erenum­ab), was stud­ied in 955 pa­tients over six months. The com­pa­ny says 50% of those pa­tients re­port­ed the high dose (140 mg) of Aimovig cut their mi­graine days by 50% or greater (com­pared to 26.6% with the place­bo). The drug met its pri­ma­ry and sec­ondary end­points. The da­ta were pub­lished in the New Eng­land Jour­nal of Med­i­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER